Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

IGKV1-5 anticorps

IGKV1-5 Reactivité: Humain, Souris WB, ELISA Hôte: Lapin Polyclonal unconjugated
N° du produit ABIN7115198
  • Antigène Tous les produits IGKV1-5
    IGKV1-5 (Immunoglobulin kappa Variable 1-5 (IGKV1-5))
    Reactivité
    Humain, Souris
    Hôte
    • 1
    • 1
    Lapin
    Clonalité
    • 2
    Polyclonal
    Conjugué
    • 2
    Cet anticorp IGKV1-5 est non-conjugé
    Application
    Western Blotting (WB), ELISA
    Purification
    Immunogen affinity purified
    Pureté
    ≥95 % as determined by SDS-PAGE
    Immunogène
    immunoglobulin kappa variable 1-5
    Isotype
    IgG
  • Indications d'application
    WB: 1:500-1:2000
    Restrictions
    For Research Use only
  • Format
    Liquid
    Buffer
    PBS with 0.02 % sodium azide and 50 % glycerol pH 7.3,
    Agent conservateur
    Sodium azide
    Précaution d'utilisation
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Stock
    -20 °C
    Stockage commentaire
    -20°C for 12 months (Avoid repeated freeze / thaw cycles.)
    Date de péremption
    12 months
  • Antigène
    IGKV1-5 (Immunoglobulin kappa Variable 1-5 (IGKV1-5))
    Autre désignation
    IGKV1-5 (IGKV1-5 Produits)
    Synonymes
    anticorps IGKV, anticorps IGKV15, anticorps L12, anticorps L12a, anticorps V1, anticorps immunoglobulin kappa variable 1-5, anticorps IGKV1-5
    Sujet
    Synonyms: Background:V segment of the variable domain of immunoglobulins light chain that participates to the antigen recognition. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens(PubMed:20176268, PubMed:22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen(PubMed:20176268, PubMed:17576170).
    UniProt
    P01602
Vous êtes ici: